Gilead Sciences, Inc. (GILD): Gilead Sciences' CEO Discusses Q3 2013 Results ... Seeking Alpha This application was supported by data from Study-10109, a single arm open label Phase 2 study of 125 patients who were refractory to both rituximab and alkylating agent chemotherapy. In this study Idelalisib achieved an overall response rate of 54 ... Gilead Sciences Announces Third Quarter 2013 Financial Results |
